Hyperuricemia: Elevations in serum uric acid have occurred. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
Bempedoic acid is associated with an increased risk of tendon rupture or injury. Discontinue treatment immediately if a patient experiences rupture of a tendon.
- Trade Names: ETC-1002; Nexletol (Esperion Therapeutics)
- Indications: An adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
- Class: Adenosine triphosphate-citrate lyase inhibitor
- Half-life: ~21 hours
- FDA Approval Date: 02/21/2020
- Clinically important, potentially hazardous interactions with:
Pravastatin, Simvastatin - Pregnancy: Discontinue bempedoic acid when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Breastfeeding is not recommended.
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
